Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biofrontera Inc. - Common Stock (NQ:BFRI)

0.9659 +0.0471 (+5.13%)
Delayed Quote Updated: 3:56 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biofrontera Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Biofrontera (NASDAQ:BFRI) Passes Minervini Trend Template With High-Growth Momentum ↗
Via Chartmill
News headline image
Biofrontera (BFRI) Q2 2026 Earnings Call Transcript ↗
Gross margins expanded 920 basis points as restructured costs offset ITC lamp restrictions. 
Via The Motley Fool
Topics Earnings
News headline image
Biofrontera (BFRI) Q1 2026 Earnings Transcript ↗
Biofrontera (BFRI) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
Biofrontera Inc. (NASDAQ:BFRI) Reports Q1 2026 Revenue and EPS Miss, Stock Falls in Pre-Market ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
A Look at Biofrontera's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
An Overview of Biofrontera's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Biofrontera (BFRI) Q4 2025 Earnings Transcript ↗
Biofrontera (BFRI) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Earnings Outlook For Biofrontera ↗
 
Via Benzinga
News headline image
Biofrontera Earnings Preview ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Biofrontera Q2 Revenue Jumps 15% ↗
Via The Motley Fool
Topics World Trade
News headline image
Biofrontera Revenue Jumps 15% in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
News headline image
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
Via ACCESS Newswire
News headline image
Earnings Scheduled For March 21, 2025 ↗
 
Via Benzinga
News headline image
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>